- Home
- XNCR vs ZYME Comparison
XNCR vs ZYME Comparison
Compare XNCR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | ZYME |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | XNCR | ZYME |
|---|---|---|
| Price | $29.30 | $27.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $22.33 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.1M | 499.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 38.87 |
| 52 Week Low | $7.80 | $13.60 |
| 52 Week High | $29.42 | $29.75 |
Technical Indicators
Market Signals| Indicator | XNCR | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 83.18 | 73.09 |
| Support Level | $11.20 | $22.10 |
| Resistance Level | N/A | $29.75 |
| Average True Range (ATR) | 1.44 | 1.10 |
| MACD | 0.58 | 0.57 |
| Stochastic Oscillator | 100.00 | 99.52 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.